Akari Therapeutics (AKTX) Current Assets (2011 - 2026)

Akari Therapeutics (AKTX) has 16 years of Current Assets data on file, last reported at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 7.17% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (up 7.17% YoY), and the FY2025 full-year result was $5.5 million, up 85.03% from the prior year.
• Current Assets slipped to $3.6 million in Q1 2026, from $5.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $13.8 million in Q4 2022 to a low of $2.7 million in Q3 2024.
• A 5-year average of $4.6 million and a median of $3.3 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets plunged 68.58% in 2023 and surged 85.03% in 2025, its largest moves.
• Tracing AKTX's Current Assets over 5 years: stood at $13.8 million in 2022, then sank by 68.58% to $4.3 million in 2023, then plunged by 32.0% to $3.0 million in 2024, then surged by 85.03% to $5.5 million in 2025, then sank by 34.29% to $3.6 million in 2026.
• Business Quant data shows AKTX's Current Assets at $3.6 million in Q1 2026, $5.5 million in Q4 2025, and $2.9 million in Q3 2025.